The Rome Trial From Histology to Target: the Road to Personalize Targeted Therapy and Immunotherapy - report from ESMO2024

Professor Andrea Botticelli presented the Rome trial results at ESMO 24 Presidential Session. Patients with advanced cancers receiving tumor-agnostic treatments based on the recommendations of a molecular tumor board had significantly better response rates and lived longer without the disease progressing than those receiving the standard of care in the ROME trial. Video: https://medicaldigest.org/scientific-contents/interview:rome-trial-histology-target-road-personalize-targeted-therapy-and-immunotherapy